March 4, 2021—Qiagen announced the global launch of the CE-IVD-marked QIAcube Connect MDx, a flexible platform for automated sample processing available now to molecular diagnostic laboratories in the U.S., Canada, the European Union, and other markets worldwide.
QIAcube Connect MDx, for in vitro diagnostic applications, offers two software environments–IVD mode for validated IVD applications and research mode—and can be used in combination with the company’s QIAamp DSP kits and PAXgene Blood RNA extraction kits. The system fully automates the lysis, bind, wash, and elute steps of the Qiagen spin columns, which can also be used manually, for DNA, RNA, and protein sample processing.
The new QIAcube Connect MDx version is compliant with medical device design standards and regulations and increases lab-process safety, the company says, with a complete IVD system, which can also be used to prepare SARS-CoV-2 and other viral samples for diagnostic testing. The platform can be used with more than 80 Qiagen kits and more than 140 standard protocols and ensures full standardization of the purification of multiple sample types.